Drug
Irinotecan sucrosofate clinical trials
Also written PEP02 and MM-398.
- studies test it
- 72
- open now
- 27
- in phase 3
- 4
- first study started
- 2006
Keep track of what changes. Save the irinotecan sucrosofate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
72 studies that test it; most in 2024 (16)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 9 |
| 2019 | 7 |
| 2020 | 1 |
| 2021 | 8 |
| 2022 | 3 |
| 2024 | 16 |
| 2025 | 6 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 27
- Phase 2
- 50
- Phase 3
- 4
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 53
PharmaEngine (5) · Ipsen (4) · CSPC Ouyi Pharmaceutical Co., Ltd. (3) · National Health Research Institutes, Taiwan (3) · Institut de Recherches Internationales Servier (2) · Federation Francophone de Cancerologie Digestive (2) · AIO-Studien-gGmbH (2) · Jiangsu HengRui Medicine Co., Ltd. (2)
Often tested with
Tested in the same studies.
Fluorouracil (17) · Leucovorin (13) · Irinotecan (11) · Oxaliplatin (9) · Capecitabine (5) · Paclitaxel (4) · Gemcitabine (3) · Trifluridine tipiracil drug combination (2)
Studies
Open first, then newest update. How each study uses irinotecan sucrosofate is read from its arms, and is right about nine times in ten.
Testing it · 72
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid TumorsRecruitingPhase 1South Plains Oncology ConsortiumNCT02013336Written as MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
- NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialRecruitingPhase 2Roswell Park Cancer InstituteNCT06821997Written as Irinotecan Sucrosofate
- Study of NALIRIFOX in Advanced Unresectable Small Bowel TumorsRecruitingPhase 2Tiago Biachi de CastriaNCT06835387Written as Nanoliposomal irinotecan
- Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal CancerNot yet recruitingPhase 2Guangdong Provincial People's HospitalNCT07521605Written as Liposomal Irinotecan (nal-IRI)
- Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .RecruitingPhase 1/2National Health Research Institutes, TaiwanNCT05927857Written as nal-IRI /Experimental
- NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic CancerNot yet recruitingPhase 1National Taiwan University HospitalNCT07314385Written as nanoliposomal irinotecan+5-FU+leucovorin
- Folfox+Irinotecan+Chemort In Esophageal CancerRecruitingPhase 2Massachusetts General HospitalNCT04656041Written as FOLFOX/ nal-IRI
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingPhase 2Ming-Yuan ChenNCT07070479Written as Irinotecan liposome
- Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLCRecruitingNot applicableFudan UniversityNCT06258642Written as Irinotecan Liposome
- Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NETEnrolling by invitationPhase 1/2National Health Research Institutes, TaiwanNCT05385861Written as nanoliposomal irinotecan plus carboplatin
- Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal CancerNot yet recruitingPhase 2Liu HuangNCT07051785Written as Fruquintinib+Irinotecan Liposome+Capecitabine
- PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer TreatmentNot yet recruitingPhase 2GERCOR - Multidisciplinary Oncology Cooperative GroupNCT07028424Written as Nal-IRI
- Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing SarcomaRecruitingPhase 2Sun Yat-sen UniversityNCT06827717Written as irinotecan liposome (II) + temozolomide + fluzoparib
- Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPCRecruitingPhase 2Sun Yat-sen UniversityNCT06657690Written as Irinotecan liposome
- NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06405490Written as Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
- Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06405139Written as Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine
- Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic CancerNot yet recruitingPhase 2Rui-hua Xu, MD, PhDNCT06700603Written as Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
- Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTCNot yet recruitingPhase 2Sir Run Run Shaw HospitalNCT06699459Written as Irinotecan Liposome
- Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic CancerNot yet recruitingPhase 1/2Harbin Medical UniversityNCT06513455Written as Irinotecan liposome（40mg/m2）
- A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06512428Written as simmitinib plus irinotecan liposome
See all 72 studies that test irinotecan sucrosofate →
Given in every arm · 20 — irinotecan sucrosofate is usual care beside what is tested
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2RecruitingPhase 2AstraZenecaNCT06219941Written as Nanoliposomal Irinotecan
- Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaRecruitingPhase 2University of Wisconsin, MadisonNCT04150640Written as Nal-IRI
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS MutationsRecruitingPhase 3SWOG Cancer Research NetworkNCT06998940Written as Irinotecan Sucrosofate
- Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaRecruitingPhase 1/2St. Jude Children's Research HospitalNCT04901702Written as Onivyde
- Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingPhase 2China Medical University, ChinaNCT07376499Written as Liposome Irinotecan
- Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or CetuximabRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06540326Written as irinotecan liposome (II)
- Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingPhase 4China Medical University, ChinaNCT06951841Written as Liposome Irinotecan
- A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)RecruitingPhase 2Belgian Group of Digestive OncologyNCT05472259Written as Nanoliposomal irinotecan
- Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal CancerRecruitingPhase 2West China HospitalNCT06341296Written as Irinotecan Liposome
- Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal CancerNot yet recruitingPhase 1/2West China HospitalNCT06341309Written as Irinotecan Liposome
- Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic CancerRecruitingPhase 2Fudan UniversityNCT06475326Written as Irinotecan liposome
- Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and SafetyRecruitingPhase 2Jiang LongNCT06531278Written as Irinotecan liposome
- NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic CancerRecruitingPhase 2Seoul National University HospitalNCT04371224Written as Irinotecan Liposomal Injection [Onivyde]
- Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic CancerNot yet recruitingPhase 1/2Tianjin Medical University Cancer Institute and HospitalNCT06259058Written as Irinotecan liposome injection
- A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine TreatmentCompletedPhase 3IpsenNCT04083235Written as Irinotecan Liposomal Injection
- Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract CancerTerminatedPhase 2CSPC Ouyi Pharmaceutical Co., Ltd.NCT05009953Written as Irinotecan Liposome Injection
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic CancerCompletedPhase 1Sumitomo Pharma America, Inc.NCT02231723Written as MM-398
- Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas CancerWithdrawnPhase 1/2Devalingam MahalingamNCT05251038Written as Liposomal Irinotecan (nal-IRI)
- A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal CancerCompletedPhase 2Fundación de investigación HMNCT04009876Written as nal-IRI
- Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic CancerStatus unknownPhase 1Benaroya Research InstituteNCT03703063Written as Onivyde
As the comparator · 3 — what is tested is compared with irinotecan sucrosofate
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerRecruitingPhase 3NRG OncologyNCT06958328Written as Irinotecan Sucrosofate
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingPhase 2ImmunityBio, Inc.NCT04390399Written as Irinotecan liposome
- A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerCompletedPhase 2Bristol-Myers SquibbNCT03336216Written as Onivyde
Codes
What other systems call irinotecan sucrosofate · ClinicalTrials.gg INT006367
- MeSH (NLM) C584112irinotecan sucrosofateOne source NLM
- UNII (FDA) OL741S3N8BIRINOTECAN SUCROSOFATEConfirmed FDA, NLM, Wikidata
- Wikidata Q27285712irinotecan sucrosofateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82676Irinotecan SucrosofateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584112 | irinotecan sucrosofate | One source NLM |
| UNII (FDA) | OL741S3N8B | IRINOTECAN SUCROSOFATE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27285712 | irinotecan sucrosofate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82676 | Irinotecan Sucrosofate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.